L-DOPA-d6

L-DOPA-d6 is the deuterium labeled L-DOPA. L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease[1][2][3].

Product Specifications

CAS Number

[713140-75-1]

Product Name Alternative

Levodopa-d6; 3,4-Dihydroxyphenylalanine-d6

UNSPSC

12352005

Target

Dopamine Receptor; Endogenous Metabolite

Type

Isotope-Labeled Compounds

Related Pathways

GPCR/G Protein; Metabolic Enzyme/Protease; Neuronal Signaling

Field of Research

Neurological Disease

Purity

99.48

Solubility

0.1 M HCl : 20mg/mL (ultrasonic; warming; adjust pH to 2 with HCl; heat to 60°C) |10 mM in DMSO|H2O : 1mg/mL (ultrasonic)

Smiles

OC([C@](N)([2H])C([2H])([2H])C1=C([2H])C(O)=C(C([2H])=C1[2H])O)=O

Molecular Formula

C9H5D6NO4

Molecular Weight

203.22

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216. |[2]Hyland K, et al. Aromatic L-amino acid decarboxylase deficiency: diagnostic methodology. Clin Chem. 1992 Dec;38 (12) :2405-10.|[3]Merims D, et al. Dopamine dysregulation syndrome, addiction and behavioral changes in Parkinson's disease. Parkinsonism Relat Disord. 2008;14 (4) :273-80. Epub 2007 Nov 7.|[4]Perez-Pardo P, et al. Additive Effects of Levodopa and a Neurorestorative Diet in a Mouse Model of Parkinson's Disease. Front Aging Neurosci. 2018 Aug 3;10:237.|[5]Park HJ, et al. Anti-allodynic effects of levodopa in neuropathic rats. Yonsei Med J. 2013 Mar 1;54 (2) :330-5.